New study aims to shield vulnerable groups from COVID-19

NCT ID NCT05556720

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether extra COVID-19 vaccine doses are safe and work well for people with weakened immune systems, such as those with HIV, organ transplants, or blood cancers. Around 960 participants will receive different booster schedules to see which one boosts their protection best. The goal is to find the best way to keep these high-risk individuals safe from severe COVID-19.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Alfred Health

    Melbourne, Victoria, 3004, Australia

  • Austin Hospital

    Heidelberg, Victoria, 3084, Australia

  • Monash Medical Centre

    Clayton, Victoria, 3168, Australia

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, 3000, Australia

  • Prince Of Wales Hospital

    Randwick, New South Wales, 2031, Australia

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, 4102, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, 5000, Australia

  • Royal Brisbane and Womens Hospital

    Herston, Queensland, 4029, Australia

  • Royal Melbourne Hospital

    Melbourne, Victoria, 3000, Australia

  • St Vincents Hospital

    Darlinghurst, New South Wales, Australia

  • St Vincents Hospital

    Fitzroy, Victoria, 3065, Australia

  • University Geelong Hospital

    Geelong, Victoria, 3220, Australia

  • Westmead Hospital

    Westmead, New South Wales, 2145, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.